Hansson, Oskar
Lund University · Skåne University Hospital
148 papers on CoChatORCID 0000-0001-8467-7286
Most cited papers
- Verified
Prediction of future Alzheimer’s disease dementia using plasma phospho-tau combined with other accessible measures
Palmqvist, S., Tideman, P., Cullen, N., Zetterberg, H., Blennow, K., Initiative, T. A. D. N., Dage, J. L., Stomrud, E., Janelidze, S., Mattsson-Carlgren, N., et al. (2021) · Nature Medicine
Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments
Cited by 524
- Verified
Interleukin-6 is elevated in the cerebrospinal fluid of suicide attempters and related to symptom severity
Lindqvist, D., Janelidze, S., Hagell, P., Erhardt, S., Samuelsson, M., Minthon, L., Hansson, O., Björkqvist, M., Träskman-Bendz, L., & Brundin, L. (2009) · Biological Psychiatry
Tryptophan and brain disordersSuicide and Self-Harm Studies
Cited by 524
- Verified
Blood biomarkers for Alzheimer’s disease in clinical practice and trials
Hansson, O., Blennow, K., Zetterberg, H., & Dage, J. (2023) · Nature Aging
Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments
Cited by 522
- Verified
Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer’s disease
Janelidze, S., Bali, D., Ashton, N. J., Barthélemy, N. R., Vanbrabant, J., Stoops, E., Vanmechelen, E., He, Y., Dolado, A. O., Triana-Baltzer, G., et al. (2023) · Brain
Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments
Cited by 522
- Verified
Blood-based NfL: A biomarker for differential diagnosis of parkinsonian disorder
Hansson, O., Janelidze, S., Hall, S., Magdalinou, N., Lees, A. J., Andreasson, U., Norgren, N., Linder, J., Forsgren, L., Constantinescu, R., et al. (2017) · Neurology
Parkinson's Disease Mechanisms and TreatmentsDementia and Cognitive Impairment Research
Cited by 506
- Verified
Plasma tau in Alzheimer disease
Mattsson, N., Zetterberg, H., Janelidze, S., Insel, P. S., Andreasson, U., Stomrud, E., Palmqvist, S., Baker, D., Tan Hehir, C. A., Jeromin, A., et al. (2016) · Neurology
Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments
Cited by 502
- Verified
Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline
Ossenkoppele, R., Pichet Binette, A., Groot, C., Smith, R., Strandberg, O., Palmqvist, S., Stomrud, E., Tideman, P., Ohlsson, T., Jögi, J., et al. (2022) · Nature Medicine
Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments
Cited by 496
- Verified
Head-to-Head Comparison of 8 Plasma Amyloid-β 42/40 Assays in Alzheimer Disease
Janelidze, S., Teunissen, C. E., Zetterberg, H., Allué, J. A., Sarasa, L., Eichenlaub, U., Bittner, T., Ovod, V., Verberk, I. M. W., Toba, K., et al. (2021) · JAMA Neurology
Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments
Cited by 494
- Verified
Accuracy of a Panel of 5 Cerebrospinal Fluid Biomarkers in the Differential Diagnosis of Patients With Dementia and/or Parkinsonian Disorders
Hall, S., Öhrfelt, A., Constantinescu, R., Andreasson, U., Surova, Y., Bostrom, F., Nilsson, C., Widner, H., Decraemer, H., Nägga, K., et al. (2012) · Archives of Neurology
Dementia and Cognitive Impairment ResearchParkinson's Disease Mechanisms and Treatments
Cited by 473
- Verified
Discriminative Accuracy of [ 18 F]flortaucipir Positron Emission Tomography for Alzheimer Disease vs Other Neurodegenerative Disorders
Ossenkoppele, R., Rabinovici, G. D., Smith, R., Cho, H., Schöll, M., Strandberg, O., Palmqvist, S., Mattsson, N., Janelidze, S., Santillo, A., et al. (2018) · JAMA
Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments
Cited by 472
- Verified
Amyloid biomarkers in Alzheimer's disease
Blennow, K., Mattsson, N., Schöll, M., Hansson, O., & Zetterberg, H. (2015) · Trends in Pharmacological Sciences
Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research
Cited by 470
- Verified
CSF A β 42/A β 40 and A β 42/A β 38 ratios: better diagnostic markers of Alzheimer disease
Janelidze, S., Zetterberg, H., Mattsson, N., Palmqvist, S., Vanderstichele, H., Lindberg, O., van Westen, D., Stomrud, E., Minthon, L., Blennow, K., et al. (2016) · Annals of Clinical and Translational Neurology
Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments
Cited by 456
- Verified
Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer's disease
Janelidze, S., Stomrud, E., Smith, R., Palmqvist, S., Mattsson, N., Airey, D. C., Proctor, N. K., Chai, X., Shcherbinin, S., Sims, J. R., et al. (2020) · Nature Communications
Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments
Cited by 450
- Verified
Highly accurate blood test for Alzheimer's disease is similar or superior to clinical cerebrospinal fluid tests
Barthélemy, N. R., Salvadó, G., Schindler, S. E., He, Y., Janelidze, S., Collij, L. E., Saef, B., Henson, R. L., Chen, C. D., Gordon, B. A., et al. (2024) · Nature Medicine
Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments
Cited by 448
- Verified
Differential roles of Aβ42/40, p-tau231 and p-tau217 for Alzheimer’s trial selection and disease monitoring
Ashton, N. J., Janelidze, S., Mattsson-Carlgren, N., Binette, A. P., Strandberg, O., Brum, W. S., Karikari, T. K., González-Ortiz, F., Di Molfetta, G., Meda, F. J., et al. (2022) · Nature Medicine
Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research
Cited by 436
- Verified
Performance of Fully Automated Plasma Assays as Screening Tests for Alzheimer Disease–Related β-Amyloid Status
Palmqvist, S., Janelidze, S., Stomrud, E., Zetterberg, H., Karl, J., Zink, K., Bittner, T., Mattsson, N., Eichenlaub, U., Blennow, K., et al. (2019) · JAMA Neurology
Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments
Cited by 435
- Verified
Blood Biomarkers to Detect Alzheimer Disease in Primary Care and Secondary Care
Palmqvist, S., Tideman, P., Mattsson-Carlgren, N., Schindler, S. E., Smith, R., Ossenkoppele, R., Calling, S., West, T., Monane, M., Verghese, P. B., et al. (2024) · JAMA
Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments
Cited by 416
- Verified
Cerebrospinal fluid analysis detects cerebral amyloid-β accumulation earlier than positron emission tomography
Palmqvist, S., Mattsson, N., Hansson, O., & Initiative, F. T. A. D. N. (2016) · Brain
Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments
Cited by 400
- Verified
Accuracy of Brain Amyloid Detection in Clinical Practice Using Cerebrospinal Fluid β-Amyloid 42: A Cross-Validation Study Against Amyloid Positron Emission Tomography
Palmqvist, S., Zetterberg, H., Blennow, K., Vestberg, S., Andreasson, U., Brooks, D. J., Owenius, R., Hägerström, D., Wollmer, P., Minthon, L., et al. (2014) · JAMA Neurology
Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments
Cited by 368
- Verified
Longitudinal plasma p-tau217 is increased in early stages of Alzheimer’s disease
Mattsson-Carlgren, N., Janelidze, S., Palmqvist, S., Cullen, N., Svenningsson, A. L., Strandberg, O., Mengel, D., Walsh, D. M., Stomrud, E., Dage, J. L., et al. (2020) · Brain
Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments
Cited by 368
- Verified
CSF biomarkers of neuroinflammation and cerebrovascular dysfunction in early Alzheimer disease
Janelidze, S., Mattsson, N., Stomrud, E., Lindberg, O., Palmqvist, S., Zetterberg, H., Blennow, K., & Hansson, O. (2018) · Neurology
Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments
Cited by 359
- Verified
Aβ deposition is associated with increases in soluble and phosphorylated tau that precede a positive tau PET in Alzheimer's disease
Mattsson-Carlgren, N., Andersson, E., Janelidze, S., Ossenkoppele, R., Insel, P., Strandberg, O., Zetterberg, H., Rosen, H. J., Rabinovici, G., Chai, X., et al. (2020) · Science Advances
Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research
Cited by 359
- Verified
Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer's disease
Palmqvist, S., Insel, P. S., Stomrud, E., Janelidze, S., Zetterberg, H., Brix, B., Eichenlaub, U., Dage, J. L., Chai, X., Blennow, K., et al. (2019) · EMBO Molecular Medicine
Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research
Cited by 353
- Verified
Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease: A Head-to-Head Comparison Against Amyloid Positron Emission Tomography and Magnetic Resonance Imaging
Ossenkoppele, R., Smith, R., Mattsson-Carlgren, N., Groot, C., Leuzy, A., Strandberg, O., Palmqvist, S., Olsson, T., Jögi, J., Stormrud, E., et al. (2021) · JAMA Neurology
Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments
Cited by 311
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free